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The endothelin-1 (ET-1) receptors were recently found to mediate pro-survival functions in
multiple myeloma (MM) cells in response to autocrine ET-1. This study investigated the
effectiveness of macitentan, a dual ET-1 receptor antagonist, in MM treatment, and the
mechanisms underlying its activities. Macitentan affected significantly MM cell (RPMI-
8226, U266, KMS-12-PE) survival and pro-angiogenic cytokine release by down-
modulating ET-1-activated MAPK/ERK and HIF-1a pathways, respectively. HIF-1a
silencing abrogated the ET-1 mediated induction of genes encoding for pro-angiogenic
cytokines such as VEGF-A, IL-8, Adrenomedullin, and ET-1 itself. Upon exposure to
macitentan, MM cells cultured in the presence of the hypoxia-mimetic agent CoCl2,
exogenous ET-1, or CoCl2 plus ET-1, down-regulated HIF-1a and the transcription and
release of downstream pro-angiogenic cytokines. Consistently, macitentan limited
significantly the basal pro-angiogenic activity of RPMI-8226 cells in chorioallantoic
membrane assay. In xenograft mouse models, established by injecting NOG mice
either via intra-caudal vein with U266 or subcutaneously with RPMI-8226 cells,
macitentan reduced effectively the number of MM cells infiltrating bone marrow, and the
size and microvascular density of subcutaneous MM tumors. ET-1 receptors targeting by
macitentan represents an effective anti-proliferative and anti-angiogenic therapeutic
approach in preclinical settings of MM.
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Multiple myeloma (MM) is a B cell malignancy arising from
post-germinative B cells or plasma cell (PC) precursors and
characterized by the accumulation of malignant PCs in the bone
marrow (BM), the onset of monoclonal gammopathy, and
eventually a significant morbidity due to organ dysfunction (1,
2). In spite of recent developments in novel therapies, MM
remains an incurable disease, accounting for about 10% of all
hematologic malignancies (3). Although various genomic
aberrations have been shown to provide PCs with the ability to
proliferate in an uncontrolled manner, increasing evidence
suggests critical roles for surface receptors with restricted
expression in malignant PCs and for BM microenvironment in
mediating MM survival, proliferation and resistance to
therapy (4).
Endothelin-1 (ET-1), originally isolated from endothelial cells
(ECs), as well as its receptors A (ETAR) and B (ETBR), referred to
as the “ET-1 axis”, exert key physiological functions in the
human cardiovascular system and in other normal tissues (5,
6). In the last two decades the ET-1 axis has been also implicated
in the development of an increasing number of tumors via
autocrine and/or paracrine activation of pathways involved in
cell proliferation, migration, invasion, epithelial-mesenchymal
transition, osteogenesis and angiogenesis (7).
We have previously demonstrated that the ET-1 axis supports
MM cell viability through autocrine activation, also anticipating
a possible paracrine triggering (8). Accordingly, we found that
both primary malignant PCs and MM cell lines were
constitutively ETAR positive, expressing ETBR in roughly half
of cases on an epigenetic dysregulation basis. MM cells and BM
microenvironment, in particular ECs, were also found to express
and release ET-1 (8). Importantly, in vitro experiments
consisting in ETAR or ETBR blockade with selective
antagonists or with the dual receptor antagonist bosentan (5)
resulted in a significantly decreased viability of MM cell lines (8).
More recently, preliminary in vitro results have demonstrated
that the dual receptor antagonist macitentan also decreases MM
cell viability (9). Interestingly, both bosentan and macitentan are
orally active drugs already licensed in clinics for the treatment of
pulmonary arterial hypertension (PAH) (10). Macitentan,
designed to improve the efficacy and tolerability of bosentan,
presents as main pharmacokinetic advantage a longer and
sustained ETAR and ETBR occupancy that allows both an
effective drug activity in the presence of elevated ET-1 levels
and a one-daily dosing (10). At present, the mechanisms
underlying the inhibitory activity of ET-1 receptor (ET-1R)
antagonists remain to be established in MM. In this tumor
context, angiogenesis is a constant hallmark of BM
microenvironment during MM progression (11). Several
studies have demonstrated that the hypoxia inducible factor-
1alpha (HIF-1a) stabilization, favored by the hypoxic MM BM
niche, induces the transcription of a few pro-angiogenic factors,
including Vascular Endothelial Growth Factor A (VEGF-A),
both in tumor and stromal cells (11). In solid tumors HIF-1a
may be controlled also in a hypoxia-independent manner by aFrontiers in Oncology | www.frontiersin.org 2number of molecules, including ET-1 (12–15). Importantly, ET-
1 stimulates hypoxic pathways promoting further ET-1
expression, thus maintaining angiogenic and pro-tumoral
responses in a positive feedback system (16). Despite the
available evidence demonstrating that HIF-1a may be
regulated in a hypoxia-independent fashion even in MM (17),
the regulatory effects of ET-1 on HIF-1a expression and related
pro-angiogenic activities in MM is currently unknown. However,
a recent network-based analysis of BM samples from patients
affected by monoclonal gammopathy of undetermined
significance (MGUS) and MM has highlighted the significant
enrichment of ET-1 in the HIF-1a signaling pathway of primary
MGUS and MM PCs (18).
Based on the aforementioned premises, aims of our work
were: i) to evaluate in vitro the mechanisms underlying the anti-
proliferative and pro-apoptotic effects exerted by macitentan in
MM cells, ii) to establish in vitro the eventual anti-angiogenic
role of macitentan and the underlying mechanisms, and ii) to test
the effectiveness of macitentan as therapeutic agent against MM
in xenograft mouse models and in a chick chorioallantoic
membrane (CAM) assay.MATERIALS AND METHODS
Cell Culture
Human MM cell lines RPMI-8226, U266, KMS-12-PE (DSMZ,
Braunschneig, Germany), representative of the pattern of
expression of ETRs in primary MM cells (8), were cultured as
previously described (8). Mycoplasma contaminations were
excluded (Mycoplasma Species kit, EuroClone, Milan, Italy).
The hypoxia-mimetic agent cobalt chloride (CoCl2, Sigma-
Aldrich, Milan, Italy) was used at a concentration of 100 µM.
Macitentan was purchased from Selleckchem, Munich,
Germany and used at a concentration of 10 µM based on
previous titration experiments (9). MM cells were treated for
24 and 48 h with 20 µmol/L of antisense oligonucleotide EZN-
2968 (anti-HIF-1a) or its negative control/scrambled EZN-
3088 (19, 20) (Enzon Pharmaceuticals Inc. Piscataway,
New Jersey).
Cell Viability and Apoptosis Assay
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay (Sigma Aldrich, Milan,
Italy), apoptosis by Annexin-V-FITC (Miltenyi Biotec, Bergisch
Gladbach, DE) and Propidium Iodide (Invitrogen, Carlsbad, CA,
USA) staining.
Reverse Transcription Quantitative Real-
Time PCR
Total RNA was isolated from MM cell lines using the SV Total
RNA Isolation System (Promega, Milan, Italy). Reverse
transcription (RT) of 1 µg RNA was performed using the
SuperScript III Reverse Transcriptase (Life Technologies,
Monza MB, Italy) according to manufacturers’ instructions.
The obtained cDNA was amplified by real-time PCR (qPCR)January 2021 | Volume 10 | Article 600025
Russignan et al. Macitentan Exerts Anti-Tumor Activities in MMusing the Fast SybrGreen MasterMix (Life Technologies, Monza
MB, Italy) and intron-spanning primers for ET-1, VEGF-A,
Interleukin-8 (IL-8), Adrenomedullin (ADM), and beta-actin
(b-ACT). Gene expression was quantified by comparative cycle
threshold (Ct) method, by normalizing Ct values to the
housekeeping gene b-ACT and calculating relative expression
values. The following primers were used: ET-1 forward 5’-CCCT
GATGGATAAAGAGTGT-3’ and reverse 5’-TCCAAGTCTAA
ATCTGTGTCCTG-3’; VEGF-A forward 5’-GAGCCTTGCCTT
GCTGCTCTA-3’ and reverse 5’-CACCAGGGTCTCGATTG
GATG-3’; IL-8 forward 5’-TACTCCAAACCTTTCCACCC-3’
and reverse 5’-AACTTCTCCACAACCCTCTG-3’; ADM
forward 5’-AAGTACTTGGCAGCTCACTCTC-3’ and reverse
5’-CCCACTTATTCCACTTCTTTCG-3’; b-ACT forward 5’-
AAAGACCTGTACGCCAACAC-3 ’ and rever se 5 ’ -
GTCATACTCCTGCTTGCTGAT-3’.
Western Blotting
Following cells lysis, protein cell extracts (40 µg) were separated
on 10% SDS-polyacrylamide gel and transferred to a
nitrocellulose membrane. Immunoblots were performed
overnight using the following primary antibodies diluted
1:1,000: anti-HIF-1a #36169, anti-phospho-ERK1/2 #4370,
anti-ERK1/2 #4695, anti-cleaved caspase-3 #9664S and anti-
GAPDH #5174S (Cell Signaling Technology, Danvers, USA),
anti-VEGF-A #46154 (Abcam, Cambridge, UK). An Ig anti-
rabbit #7074S 1:1000 secondary antibody was used (Cell
Signaling Technology, Danvers, USA). Blots were then
developed using ECL (Merck, Milan, Italy) and images were
acquired by Image Quant Las 4000mini (GE Healthcare Life
Sciences, Milan, Italy).
In Vivo Studies
NOD/Shi-scid/IL-2Rgnull (NOG) mice were purchased from
Taconic (Germantown, NY, USA). Four groups of five four-to
six-week-old female mice were subcutaneously injected with 5 ×
106 RPMI 8226 cells. At day +7 post-injection, mice were daily
treated with macitentan (30 mg/kg) (21) or vehicle (Methocell
0.05% and TWEEN 80 0,05%) per os for four weeks. At the end
of treatment mice were sacrificed and tumor masses were
measured with a caliper (tumor mass in mm3 was calculated
using the formula p/6 larger diameter x smaller diameter2) and
analyzed by immunohistochemistry (IHC). Simultaneously,
four groups of five 4–6-week-old mice animals totally
irradiated (1.2 Gy,137Cesium source) were injected into the
tail vein with 2 × 106 U266 cells. At day 7 post-injection,
mice were daily treated with macitentan (30 mg/kg) or vehicle
(Methocell 0,05% and TWEEN 80 0,05%) per os. Following a 7-
day treatment, mice were sacrificed, and MM BM burden was
evaluated as percentage of viable human CD45+CD138+ cells
over total viable human CD45+ TOPRO3 negative cells. The
day of beginning and the length of macitentan treatment were
established based on preliminary experiments. RPMI-8226 and
U266 cell lines were chosen on the basis of the literature data for
subcutaneous and intra-tail injection of MM cell lines,
respectively (22).Frontiers in Oncology | www.frontiersin.org 3Flow Cytometric Analysis
BM cells were flushed from the tibia of adult NOD/Shi-scid/IL-
2Rgnull (NOG) mice, red blood cells lysed, and washed twice in
PBS. Subsequently, mice BM cells were stained with TOPRO-3
APC, anti-CD45 PE, anti-CD138 V500 (Biolegend, London, UK)
and anti-HIF-1a (Cell Signaling Technology, Danvers, USA).
Median fluorescence intensity (MFI) was measured by
FacsCanto flow cytometer (Becton-Dickinson, New Jersey,




After antigen retrieval, sections were incubated with anti-
Cleaved Caspase-3 (rabbit polyclonal, diluted 1:600, Trevigen)
or with PECAM-1 (goat, clone M-20, diluted 1:600 from Santa
Cruz Biotechnology). Reactions were revealed using Goat-on-
Rodent-HRP-Polymer (BIOCARE) or EnVision+System HRP
Labelled polymer anti-Rabbit (Dako, Agilent, Santa Clara, CA,
USA) followed by DAB. Slides were digitalized using ScanScope
CS Slide Scanner (Aperio Technologies, Leica, Milan, Italy) at
40 x magnifications and analyzed by Image Scope. PECAM and
Caspase-3 analysis were obtained using Positive pixel count v9
(Leica, Milan, Italy).
Enzyme-Linked Immunosorbent Assay
ET-1, IL-8 and ADM levels were measured in 24 h supernatants
from MM cell cultures by ET-1 Quantikine ELISA kit (R&D
System, Minneapolis, USA, Canada), IL-8 ELISA (Mabtech,
Nacka Strand, Sweden), and ADM Quantikine ELISA kit
(R&D System, Minneapolis, USA, Canada). Assay sensitivity
was 0.207 pg/mL for ET-1, 4 pg/ml for IL-8, and 7.5 pg/ml
for ADM.
Chorioallantoic Membrane Assay
CAM assay was established as previously described (23). Briefly,
alginate beads were prepared by dissolving 6% (w/v) alginic acid
sodium salt (Sigma Aldrich) in sterile milliQ H2O overnight at
4°C. Then, 2 µL of the solution were added with 2 µL of PBS
containing 1.5 x104 RPMI-8226 cells, in the presence of either
0.1% DMSO (vehicle) or macitentan to a final concentration
equal to 20 or 40 pmol/pellet. The gelation reaction was obtained
by exposing the pellets to 0.1 M CaCl2. Alginate beads were then
placed on the top of the embryo CAM of fertilized White
Leghorn chicken eggs at day 11 of incubation. After 72 h,
newly formed microvessels converging towards the implant
were counted under a stereomicroscope (STEMI-SR, Zeiss,
Germany) at × 5 magnification.
Statistical Analysis
Mice sample size was chosen as previously described (24).
ANOVA test was used to analyze the differences among
multiple means. Expression of treatment with respect to
controls was analyzed using Student’s t test. Statistical analyses
were performed by GraphPad PRISM® version 5-0c.January 2021 | Volume 10 | Article 600025
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Macitentan Exerts Anti-Proliferative
Effects in Multiple Myeloma Cells by
Inhibiting the MAPK/ERK and Pro-Survival
Pathways
Preliminary results had shown that macitentan exerts significant
anti-survival and anti-proliferative activities towards RPMI-
8226, U266, and KMS-12-PE cells (9) (Supplementary Figure
1), the first two cell lines expressing both ETAR and ETBR on the
membrane, the third one (KMS-12-PE cells) ETAR only. To
evaluate the mechanisms underlying the anti-proliferative action
exerted by macitentan, we examined the MAPK/ERK signaling
pathway, which is known to be involved in ET-1-mediated
autocrine and paracrine pro-tumorigenic functions (7). As
shown by the Western blots in Figure 1A, basal levels of p-
erk1/2 were found in RPMI-8226, U266, and KMS-12-PE cells
under resting conditions. Upon 48 h culture with ET-1, MM cell
lines further increased p-erk1/2 expression. By densitometric
analysis, macitentan significantly reduced p-erk1/2 levels both in
resting and ET-1-stimulated cell lines (Figure 1A), thus showing
its capacity to antagonize either the autocrine (8) and paracrine
activation of ET-1 axis in MM cells. We then observed that the
expression of cleaved caspase-3 increased in both resting and ET-
1-stimulated cells treated with macitentan, thus better
characterizing the pathways downstream of ET-1Rs that may
be involved in the resistance to apoptosis (Figure 1B). Taken
together, our findings confirm the pro-survival activity of the ET-
1 axis and its role as therapeutic target in MM. The capacity of
macitentan to interfere with major signaling pathways elicited by
both autocrine and exogenous ET-1 is also highlighted.
Macitentan Inhibits Tumor Growth in
Multiple Myeloma Xenograft Mouse
Models
We next investigated whether macitentan may affect MM cell
viability and growth in vivo. In order to address this question,
we analyzed the effects of treatment with macitentan in NOG
mice injected with MM cells either via intra-caudal vein
or subcutaneously.
A first group of 20 mice was injected intra-venously with
2x106 U266 cells. Starting from the engraftment (day +7 from
injection) and for the subsequent 7 days, mice were treated orally
either with macitentan at a dosage of 30 mg/kg (n=10) or with
vehicle only (n=10), and then sacrificed. Notably, following
injection of U266 cells, control mice displayed hair alterations,
weight loss and limbs paralysis as for disease progression (not
shown). BM cells, collected by tibial flushing from macitentan-
treated and untreated mice, were then analyzed for viability by
flow cytometry after anti-CD45 and anti-CD138 staining
(Supplementary Figure 2). The viable (i.e., TOPRO-3
negative) CD138+ cell fraction was significantly reduced in BM
samples from macitentan-treated mice as compared to controls
(11 vs 44%, p=0.001) (Figure 2A), thus showing that macitentan
can reach effective therapeutic concentrations in the tissue
primarily affected by MM cell expansion.Frontiers in Oncology | www.frontiersin.org 4A second group of 20 mice was injected subcutaneously with
5x106 RPMI-8226 cells and monitored for subcutaneous tumor
mass development. Starting from day +7 after injection, mice
were treated with a macitentan daily oral dose of 30 mg/kg, 5
days a week, for 4 weeks (n=10) or with vehicle only (n=10), and
then sacrificed. At the end of treatment all animals developed
well-delimited tumors in the site of injection that were removed
and measured. As shown in Figure 2B, tumor masses from
macitentan-treated mice had a median size significantly reduced
as compared to controls (125 mm3 vs 370 mm3, p=0.003).
Consistently with previous in vitro findings, higher expression
of cleaved caspase-3 was observed in histological specimens from
macitentan-treated mice as compared to controls (Figure 2C).
Interestingly, PECAM1 staining revealed a significantly
diminished microvascular density (MVD) in RPMI-8226
tumor masses from macitentan-treated mice, as compared to
controls (Figure 2D), thus suggesting that in MM macitentan
could also exert an anti-angiogenic activity.
Overall, our in vivo findings extend previous in vitro results
regarding the anti-proliferative effects of ET-1Rs blockade in
MM cells and support the role for macitentan as an effective
therapeutic agent against MM. In addition, the significantly
reduced MVD observed in tumors from treated mice as
compared to controls anticipates a possible anti-angiogenic
activity of macitentan in MM.
Macitentan Downregulates Hypoxia
Inducible Factor-1alpha, a Crucial
Mediator of Multiple Myeloma
Angiogenesis
HIF-1a plays a crucial role in the adaptive responses to hypoxia
of tumor cells through transcriptional activation of downstream
genes required for tumor survival and progression, including
those for angiogenesis (25). It is known that MM cells up-
regulate HIF-1a in the hypoxic BM niche, which in turn
promotes MM progression (26). Previous studies demonstrated
the capacity of ET-1 to induce HIF-1a in solid tumors (12–14).
In addition recent network-based analysis highlighted the
significant ET-1 gene enrichment in the HIF-1a signaling
pathway of PCs from BM samples of patients affected by MM
and MGUS (18). Consequently, we tried to assess whether ET-1
was capable of up-regulating HIF-1a in MM, similarly to
hypoxia. We therefore evaluated HIF-1a protein levels in
RPMI-8226, U266, and KMS-12-PE cells cultured for 48 h in
the presence of the hypoxia-mimetic agent CoCl2, ET-1, or their
combination. As shown in Figure 3 both CoCl2 and ET-1 as well
as their combination induced HIF-1a in all cell lines.
Interestingly, ET-1 induced HIF-1a similarly to CoCl2 in
RPMI-8226 and, at higher levels, in U266 and KMS-12-PE
cells (p<0,001). The combination of ET-1 plus CoCl2 promoted
a further induction of HIF-1a in RPMI-8226 and U266 cells.
Importantly, macitentan significantly inhibited both CoCl2- and
ET-1-induced HIF-1a, also reducing the combined effect of
CoCl2 plus ET-1 (Figure 3). Taken together these results
demonstrate that, in MM, the ET-1 axis activates and
potentiates HIF-1a expression, which is significantly down-January 2021 | Volume 10 | Article 600025
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FIGURE 1 | Macitentan modulates basal and ET-1-induced p-erk1/2 phosphorylation and activates caspase 3 cleavage. (A) Western blots showing the up-
regulation of basal p-ERK following treatment of MM cell lines with ET-1 (100 nM) and the down-modulating effects of macitentan (10 µM) on both basal and ET-1-
induced p-ERK over 48 h culture (upper). Densitometric evaluations reporting mean ± SEM (lower). (B) Western blots showing the appearance of cleaved form of
caspase 3 following treatment of MM cell lines with macitentan (10 µM) over 48 h culture in the presence or absence of ET-1 (100 nM) (upper). Densitometric
evaluations reporting mean ± SEM (lower). GAPDH was used as internal control. Each experiment is representative of three replicates. MAC, Macitentan. *p < 0.05,
**p <0.005, ***p < 0.001, ****p < 0.0001.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 6000255
Russignan et al. Macitentan Exerts Anti-Tumor Activities in MMregulated by macitentan. Consistently with these results, we
observed by flow cytometry that viable (i.e., TOPRO3 negative)
U266 cells isolated from BM of macitentan-treated mice
displayed a lower HIF-1a median fluorescence intensity (MFI)
than controls (219 vs 12, p<0,001) (Supplementary Figure 3).Frontiers in Oncology | www.frontiersin.org 6Macitentan Disrupts the Mutual
Dependence Between ET-1 Axis
and Hypoxia Inducible Factor-1alpha
Our previous work had shown that both MM and BM




FIGURE 2 | Macitentan inhibits MM cell viability in BM and reduces tumor masses of xenograft mouse models. (A) Percentage of viable CD138+ cells identified by
cytofluorimetric analysis in BM of NOG mice intravenously injected with U266 cells and undergoing treatment with vehicle or macitentan for 7 days (left), and graph
representing the significant reduction of viable CD138+ cells in the macitentan-treated group (right). (B) Representative image of tumor masses from NOG mice
subcutaneously injected with RPMI-8226 cells and undergoing 5 weeks treatment with vehicle or macitentan for 5 days/week (left), and graph representing the
significant reduction of tumor volumes in the macitentan-treated group (right). (C) Immunostaining of cleaved caspase 3 performed on formalin fixed paraffin-
embedded samples (n=12) obtained from tumor masses of mice treated with vehicle or macitentan (left), and graph representing the significant increase of cleaved
caspase 3 in tumor masses from macitentan-treated animals. (D) Immunostaining of PECAM-1 performed on formalin fixed paraffin-embedded samples (n=12)
obtained from tumor masses of mice treated with vehicle or macitentan (left), and graph representing the significant reduction of PECAM-1 staining in macitentan-
treated animals. Original magnification x40. *p < 0.05, **p < 0.005, ***p < 0.001.January 2021 | Volume 10 | Article 600025
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pro-tumor activity of the ET-1 axis in MM (8). As ET-1 gene
transcription is dependent on HIF-1a, we hypothesized that MM
cells could increase the transcription and the release of ET-1 in the
hypoxic BM niche. To evaluate whether MM cells are capable of
expressing and releasing higher levels of ET-1 in hypoxic
conditions, thus self-sustaining the pro-tumor activity of the ET-1
axis, we cultured RPMI-8226, U266 and KMS-12-PE cells in the
presence of CoCl2. As reported in Figures 4A, B, upon exposure to
CoCl2MMcells increased significantlyET-1 gene transcriptionand
release, which were reduced by the addition of macitentan.
Interestingly, ET-1 gene transcription increased upon culture of
MMcells with ET-1 itself and by its combinationwith CoCl2, while
being significantly down-regulated by macitentan in all
experimental settings (Figure 4A). Finally, upon exposure to
ET-1, MM cells HIF-1a- silenced (Supplementary Figures 4A,
B) displayed a significantly reduced ET-1 gene transcription
(Figure 4C), thus indicating that the regulation of ET-1
expression is mediated by HIF-1a.
Overall, these findings indicate that ET-1 axis and HIF-1a
pathway in MM are mutually dependent in an autocrine and
paracrine fashion, and that macitentan may target crucial HIF-
1a-dependent pathways.Macitentan Exerts a Significant
Antiangiogenic Activity by
Downmodulating Cytokine Expression
and Release by Multiple Myeloma Cells
Angiogenic switch represents a crucial step towards MM
progression (27). Several experimental evidences have already
shown that, in MM cells, hypoxic condition targets the
transcription of a number of pro-angiogenic cytokines genes via
HIF-1a, including VEGF-A, IL-8, and ADM (28, 29). As ET-1 up-Frontiers in Oncology | www.frontiersin.org 7regulates HIF-1a, we evaluated whether the transcription of HIF-
1a-dependent pro-angiogenic genes in MM may be mediated by
the ET-1 axis. We thus evaluated by RT-qPCR the transcription of
VEGF-A, IL-8 and ADM in RPMI-8226, U266 and KMS-12-PE
cells exposed for 3 h to CoCl2, ET-1, or their combination. ET-1,
either alone or in combination with CoCl2, up-regulated in all cell
lines the expression of VEGF-A, IL-8 and ADM genes, which in
turn were effectively down-modulated by macitentan (Figure 5).
The capacity of ET-1 to increase VEGF-A, IL-8 and ADM gene
transcription was significantly reduced in HIF-1a-silenced MM
cells (Supplementary Figure 5), further reinforcing the existence of
an interplay among ET-1 axis, hypoxia and angiogenesis in MM.
The pro-angiogenic activity of the ET-1 axis in MM was then
evaluated by measuring VEGF-A, IL-8 and ADM protein levels in
RPMI-8226,U266, andKMS-12-PE cells cultured in thepresenceof
CoCl2, ET-1, or their combination. As shown by Western blots in
Figure 5B, VEGF-A, constitutively expressed at low levels by all cell
lines, was significantly up-regulated by either CoCl2 or ET-1, alone
or in combination. In all experimental settings, macitentan down-
regulated the expression of VEGF-A. As demonstrated by ELISA
analysis, the supernatants fromRPMI-8226, U266 andKMS-12-PE
cells cultured with CoCl2, ET-1, or their combination, contained
increased concentrations of IL-8 and ADM, which in turn were
significantly reduced by the addition of macitentan (Figure 5C).
Overall, these findings indicate a crucial role of the ET-1 axis as a
mediator of angiogenesis in MM. More importantly, our data
highlight the capacity of macitentan to interfere with the
expression and release of pro-angiogenic cytokines, such as ET-1
itself, VEGF-A, IL-8 and ADM through the down-modulation of
HIF-1a in MM cells.
To demonstrate that macitentan exerts a direct anti-angiogenic
activity in MM in vivo, we subsequently set-up a chick embrio
CAM assay using RPMI-8226 cells, which express basal levels of
VEGF-A, IL-8 and ADM, other than ET-1 (Figures 4B, 5B, C).FIGURE 3 | Macitentan significantly reduces ET-1-induced HIF-1a expression. Western blots showing the effects of macitentan (10 µM) on up-regulation of HIF-1a in
MM cell lines exposed to the hypoxia-mimetic agent CoCl2 (100 µM), to ET-1 (100 nM), and to CoCl2 plus ET-1 for 48 h (upper). Densitometric evaluations reporting
mean ± SEM (lower). GAPDH was used as internal control (lower). Each experiment is representative of three replicates. *p < 0.05, **p < 0.005, ***p < 0.001.January 2021 | Volume 10 | Article 600025
Russignan et al. Macitentan Exerts Anti-Tumor Activities in MMRPMI-8226 cells were therefore grafted in an alginate pellet and
the number of newly formed vessels converging towards them
was counted. As shown in Figure 6, when grafted on the top of the
chick embryo CAM, RPMI-8226 cells induced a potent angiogenic
response, which was significantly inhibited by the presence of
increasing concentrations of macitentan, clearly unveiling its
anti-angiogenic activity in MM.Frontiers in Oncology | www.frontiersin.org 8DISCUSSION
In this study we show that the ET-1 axis increases MM cell
growth and angiogenesis both in an autocrine and paracrine
manner. Of translational relevance, we demonstrate that in
xenograft mouse models macitentan impairs MM cell growth
and decreases MM-related vascularity. In our opinion, these dataA
B
C
FIGURE 4 | ET-1 expression and release are HIF-1a-dependent. (A) RT-qPCR analysis showing ET-1 mRNA expression in MM cell lines treated with CoCl2 (100
µM), ET-1 (100 nM) and CoCl2 plus ET-1 alone or in combination with macitentan (10 µM) for 3 h, normalized on b-actin mRNA. Data represent the mean value ±
SEM. (B) ELISA measuring ET-1 levels in 48 h supernatants from MM cell lines treated with CoCl2 alone or in combination with macitentan. Data represent mean
value ± SEM. (C) RT-qPCR analysis showing ET-1 mRNA expression in MM cell lines HIF-1a-silenced with the antisense oligonucleotide EZN-2968 or scrambled
oligonucleotide (20 µmol/L) for 48 h, and exposed to ET-1 100 nM. ET-1 mRNA expression was normalized on b-actin. Each experiment is representative of three
replicates. **p < 0.005, ***p < 0.001.January 2021 | Volume 10 | Article 600025
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B
C
FIGURE 5 | Macitentan inhibits pro-angiogenic cytokine gene transcription and protein production/release. (A) RT-qPCR analysis of VEGF-A, IL-8 and ADM mRNA
expression in MM cell lines treated with CoCl2 (100 µM), ET-1 (100 nM) and CoCl2 plus ET-1 in the absence or presence of macitentan (10 µM) for 3 h, normalized
on b-actin mRNA. Data represent the mean value ± SEM. (B) Western blot showing the modulation of VEGF-A in MM cell lines stimulated with CoCl2, ET-1, and
CoCl2 plus ET-1 in the absence or presence of macitentan (10 µM) for 48 h (upper). GAPDH was used as internal control. Each experiment is representative of three
replicates. Densitometric evaluations reporting mean ± SEM (lower). (C) IL-8 and ADM levels measured by ELISA in supernatants from MM cell lines stimulated with
CoCl2 (100 µM), ET-1 (100 nM), and CoCl2 plus ET-1 in the absence or presence of macitentan (10 µM) for 48 h. Data represent mean value ± SEM. Each
experiment is representative of three replicates. *p < 0.05, **p < 0.005, ***p < 0.001.Frontiers in Oncology | www.frontiersin.org January 2021 | Volume 10 | Article 6000259
Russignan et al. Macitentan Exerts Anti-Tumor Activities in MMreinforce and extend the role of ET-1 axis as therapeutic target in
MM (8, 9, 30).
Our in vitro experiments have shown that MM cells express
and release increased levels of ET-1 when cultured with CoCl2,
the latter mimicking the hypoxic conditions of the BM niche.Frontiers in Oncology | www.frontiersin.org 10Similar to CoCl2, exogenous ET-1 increased HIF-1a levels in
MM cells by up-regulating the transcription of HIF-1a-
dependent pro-angiogenic genes such as VEGF-A, IL-8, ADM,
and ET-1 itself. Under the same experimental settings,
macitentan effectively down-modulated HIF-1a, the expressionFIGURE 6 | Anti-angiogenic activity of macitentan in CAM assay. Left, graphic representation of the number of newly formed vessels counted at day 14 in chick embryo
CAMs implanted at day 11 with alginate beads containing DMSO only or 1.5 x104 RPMI-8226 cells plus DMSO or 1.5 x104 RPMI-8226 cells plus increasing amounts of
macitentan. Data are the mean ± SEM of 11-14 eggs per experimental point in two independent experiments. **p < 0.01; ***p < 0.001 versus untreated (ANOVA). Right,
representative images of CAMs grafted with RPMI-8226 cells in the absence (upper panel) or in the presence (lower panel) of 40 pmol of macitentan.FIGURE 7 | Graphic representation: mechanisms whereby macitentan inhibits MM cell growth and angiogenesis. MM cells express ETAR or ETAR and ETBR.
Blockade of ET-1Rs by macitentan targets not only MM cell proliferation/viability (through ERK1/2 down-modulation), but also MM cell angiogenic activity (through
HIF-1a down-modulation). According to data in literature, macitentan could also target ET-1 axis in endothelial cells (ECs) through ETBR antagonism.January 2021 | Volume 10 | Article 600025
Russignan et al. Macitentan Exerts Anti-Tumor Activities in MMof HIF-1a-dependent pro-angiogenic genes, and the production/
release of the corresponding cytokines. These findings appear of
particular interest, as HIF-1a may increase angiogenesis in MM
BM under the combined influence of hypoxia and ET-1. In
agreement with such hypothesis, HIF1-a-silenced MM cells
failed to express VEGF-A, IL-8 and ADM, other than ET-1
itself, upon exposure to exogenous ET-1. Significant anti-
proliferative effects in terms of MM cell viability in BM and
subcutaneous tumor growth were observed in vivo in MMmouse
models treated with macitentan. In the same models, residual
viable MM cells in BM showed a reduced expression of HIF-1a,
while subcutaneous masses displayed a significantly lower MVD
than controls. In line with these findings, macitentan effectively
impaired the induction of angiogenesis by MM cells in CAM
assay. Overall, the set of experimental evidence here provided
underscores a particular sensitivity of MM cells towards ET-1Rs
blockade, which can hamper ET-1-triggered crucial MM pro-
survival and pro-angiogenic signaling pathways, such as those
involving MAPK/ERK (31) and HIF-1a (28, 32), respectively.
MM is known to interplay through mutual pro-survival/
proliferative signals with the BM microenvironment (4, 33), the
latter being characterized by angiogenesis as a hallmark of disease
progression. Novel drugs targeting not only tumor cells, but also
the BMmicroenvironment have been proved to be highly effective
in MM (31). Under this perspective, oral immunomodulatory
imide drugs, including thalidomide, lenalidomide, pomalidomide
as well as proteasome inhibitors, such as bortezomib, are currently
used in clinical protocols due to their anti-proliferative and anti-
angiogenic proprieties (27). Our experimental evidence together
with literature data indicate that macitentan may also target both
tumor and BM microenvironment, as ET-1 axis drives autocrine
and paracrine pro-survival and pro-angiogenic signals in both
malignant PCs and ECs. Indeed, not only MM cells (8), but also
ECs (10) release increased levels of ET-1 through a HIF-1a-
dependent activation (34), further reinforcing the hypothesis of an
ET-1 axis-mediated mutual support between MM cells and ECs in
the hypoxic BMmicroenvironment. Furthermore, based on ETAR
and ETBR expression by MM cells (8) and ETBR by ECs (10), ET-
1Rs blockade could target not only MM cells, but also the
formation of new vessels, therefore exerting a potent therapeutic
action against both MM and angiogenesis. Worthy of note, the
expression of HIF-1a by ECs in BM has been also pointed as a
therapeutic target inMM (35). At the same time, ET-1Rs blockade
could inhibit the autocrine activation of ET-1-axis in both MM
cells and ECs (10, 35, 36), thus interrupting an autocrine other
than a paracrine pathogenic loop. Of interest, due to its
pharmacokinetic properties (10), macitentan can be effective
towards MM cells expressing ETAR only or ETAR and ETBR, as
well as towards ETBR positive ECs (Figure 7).
ET-1 axis has been considered for a long time a possible
therapeutic target in a number of solid tumors, though with
fluctuating results (16). As previously stated, macitentan is a
second-generation dual receptor antagonist that has been approved
since 2013 for the therapy of PAH in the United States and Europe
(37, 38).Macitentan does not appear to require dosage adjustment in
patients with hepatic and renal impairment (37), thus presenting aFrontiers in Oncology | www.frontiersin.org 11toxicity profile potentially suitable for the treatment ofMM, a disease
often associated with renal failure. Additionally, macitentan was
shown to sensitize tumor cells to different cytotoxic and targeted
agents in various preclinical tumor models, including colorectal
cancer, glioblastoma, breast, and lung brain metastasis (39). In this
regard, our preliminary in vitro findings indicated that macitentan
can be administered in combination with other drugs already used
for MM treatment. Accordingly, we found that macitentan exerts a
synergistic action towards MM cells with the proteasome inhibitor
bortezomib (9) and with the oral immunomodulatory imide drug
pomalidomide (R.A. and C.T. unpublished results).
Overall, our data point out a potential therapeutic role for
macitentant in MM patients that deserves to be exploited in
further preclinical and phase 1–2 clinical studies, either alone or
in combination with other anti-MM drugs.DATA AVAILABILITY STATEMENT
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